IGF2 and head and neck squamous cell carcinoma: To this end, we analysed F4/80+ macrophages, FSP-1+ fibroblasts and VEGFR+ VE cells along with the IGF-2 expression in HNSCC tissues resected from patients (n=6) who enroled in a clinical trial with cixutumumab.